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Abstract
Background: Dengue virus (DENV) infection can range in severity from mild dengue fever (DF) to severe dengue
hemorrhagic fever (DHF) or dengue shock syndrome (DSS). Changes in host gene expression, temporally through the
progression of DENV infection, especially during the early days, remains poorly characterized. Early diagnostic markers for
DHF are also lacking.
Methodology/Principal Findings: In this study, we investigated host gene expression in a cohort of DENV-infected subjects
clinically diagnosed as DF (n = 51) and DHF (n = 13) from Maracay, Venezuela. Blood specimens were collected daily from
these subjects from enrollment to early defervescence and at one convalescent time-point. Using convalescent expression
levels as baseline, two distinct groups of genes were identified: the ‘‘early’’ group, which included genes associated with
innate immunity, type I interferon, cytokine-mediated signaling, chemotaxis, and complement activity peaked at day 0–1
and declined on day 3–4; the second ‘‘late’’ group, comprised of genes associated with cell cycle, emerged from day 4 and
peaked at day 5–6. The up-regulation of innate immune response genes coincided with the down-regulation of genes
associated with viral replication during day 0–3. Furthermore, DHF patients had lower expression of genes associated with
antigen processing and presentation, MHC class II receptor, NK and T cell activities, compared to that of DF patients. These
results suggested that the innate and adaptive immunity during the early days of the disease are vital in suppressing DENV
replication and in affecting outcome of disease severity. Gene signatures of DHF were identified as early as day 1.
Conclusions/Significance: Our study reveals a broad and dynamic picture of host responses in DENV infected subjects. Host
response to DENV infection can now be understood as two distinct phases with unique transcriptional markers. The DHF
signatures identified during day 1–3 may have applications in developing early molecular diagnostics for DHF.
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Introduction
Dengue viruses (DENV) are arthropod-borne single stranded RNA
viruses of the family Flaviviridae, genus Flavivirus. There are 4 closely
related, but antigenically distinct serotypes, DENV-1,-2,-3, and -4.
DENVs are endemic in more than 100 tropical and subtropical
countries of the world. Presently, no specific therapies or vaccines are
available to treat the diseases or to prevent DENV transmission [1,2].
Typically, febrile illnesses begin 5–7 days from the initial DENV
infection by an infected mosquito. The virus propagates in the
human host and the viremia titer in the host’s peripheral blood
peaks during the early days (first 2–3 days) of acute illness, which is
then followed by a steep decline [3]. Illnesses caused by DENV
infection include undifferentiated dengue fever (DF), dengue
hemorrhagic fever (DHF), and dengue shock syndrome (DSS)
[4,5]. According to the WHO’s 1997 guidelines [6,7], DF is an
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acute febrile illness with two or more manifestations of headache,
retro-orbital pain, myalgia, arthralgia, rashes, etc. Symptoms of
DF can last for 2–7 days. A DHF case is diagnosed by persistent
high fever, hemorrhage tendency, signs of plasma leakage ($20%
increase in hemoconcentration or hypoprotemia, pleural effusion
or ascites), and thrombocytopenia (platelet counts #100,000/
mm3). DHF is further classified into 4 grades according to the
severity of bleeding and plasma leakage. DSS refers to DHF
grades III and IV, which, if not diagnosed and treated in a timely
manner, can lead to death [6–9].
The pathogenic feature of severe dengue disease is a transient
increase in vesicular permeability, resulting in plasma leakage.
DENV-infection rigorously activates the host innate immune
system, which contributes to early anti-viral defense, but may
concomitantly also contribute to the development of plasma
leakage [3,10]. Analyses of host genome-transcript patterns have
revealed multiple gene expression profiles associated with dengue
infection: NF-kB-initiated immune responses [11], type I interfer-
on (IFN), ubiquitin proteasome pathway [11], cell cycle and
endoplasmic reticulum (ER) [12], genes involved in T and B cell
activation, surface marker expression, immunoglobulin, comple-
ment activation, and inmate immunity [12–14]. Some of these
genes are differentially expressed in DF vs. DHF or DSS patients
[12–14]. These studies demonstrated a powerful way for exploring
the roles of host immune responses to DENV infection, as well as
identifying disease severity markers using peripheral blood
mononuclear cells (PBMCs) without purifying the immune cell
subsets or manipulating the cells.
In this study, the dynamics of gene expression were analyzed in
cohorts of clinically defined DF and DHF subjects. The study
established an evolving picture of the host immune response
throughout the entire progression of dengue disease, from as early
as fever onset to early defervescence. In addition, the study
identified key genomic signatures that might be useful for the
future development of early diagnosis of severe dengue disease.
Materials and Methods
Ethics
All of the procedures were conducted in accordance with the
ethical standards of the Naval Medical Research Center Institu-
tional Review Board and with the Helsinki Declaration of 1975, as
revised in 1983. Prior to participating in the study, an informed
written consent was obtained from each participant or from their
parents or legal guardians. The Naval Medical Research Center
Institutional Review Board, in compliance with all Federal
regulations governing the protection of human subjects, approved
the study protocol (NMRCD.2005.0007). This study was also
approved by the Comite´ de Bioe´tica del Instituto de Investiga-
ciones Biome´dicas de la Universidad de Carabobo (CBIIB-UC), in
Maracay, Venezuela.
Patient enrollment, diagnosis of DENV, clinical
monitoring and specimen collection
Approximately 2500 residents in the city of Maracay,
Venezuela, participated in an active surveillance program for
DENV transmission. The subjects were monitored for febrile
illness through visits or phone calls three times a week. The
subjects who were five years of age and older, with a fever duration
of less than 120 hours and with two or more of the following
symptoms: myalgia, athralgia, leucopenia, rash, headache, lymph-
adenopathy, nausea, vomiting, positive tourniquet test, thrombo-
cytopenia and hepatomegaly (World Health Organization, Den-
gue hemorrhagic fever: diagnosis, treatment, prevention and
control. 2nd ed. Geneva: WHO; 1997), were enrolled in this study
by nurses and physicians of the field team from the Febrile
Surveillance Cohort, and by site physicians from local outpatient
clinics (Ambulatorio 23 de Enero, Ambulatorio la Candelaria,
Ambulatorio Efrain Abad Y Ambulatorio del Norte), and from
two metropolitan reference hospitals (Hospital Central de Mar-
acay and Hospital Ivss Jose Maria Caraban˜o Tosta). Blood
samples were obtained by standard venipuncture procedures in a
VacutainerH collection tube with anticoagulant. An initial blood
sample was taken upon enrollment for DENV serotype determi-
nation using Taqman-based RT-PCR. Only if DENV infection
was confirmed by RT-PCR, then serial blood samples were
collected at 24, 48 and 72 hours following the initial sample, and
one to two samples within 0–72 hours post-fever defervescence
and one sample at $20 days (convalescent period) following the
initial sample. Viremia levels were measured using quantitative
RT-PCR at enrollment and at 24, 48 and 72-hour specimens.
Clinical symptoms were monitored and recorded at every visit.
Separation of plasma and PBMCs was performed by gradient
centrifugation over Histopaque-Ficoll (Sigma, St. Louis, MO). The
plasma and PBMCs were stored at 270uC.
For the confirmed DENV cases, serum IgM was measured from
the samples at acute phase and convalescent phase using enzyme-
linked immunosorbant assays (ELISA) [15,16]. The primary
infection was determined using IgM serology: elevated IgM titers
($1:100) without detectable PRNT in the acute sample, and
elevated IgM levels in the convalescent sample. To determine the
prevalence and cumulative incidences of DENV infections, PRNT
titers were measured in the sera obtained from acute specimens
[17] as previously described [16,18].
Hematological analysis
Complete blood cell counts were performed for each blood
sample collected using the QBC automated system according to
the manufacturer’s instructions (Becton-Dickinson 1996). The
QBC STAR measures 9 important CBC hematological parame-
ters: hematocrit, hemoglobin, MCHC (mean corpuscular hemo-
globin concentration), platelet count, white blood cell count,
granulocyte count and percentage, and lymphocyte/monocyte
count and percentage.
RT-PCR
Viral RNA was prepared from 140 mL sera using QIAamp
ViralRNA Mini Kits according to the manufacturer’s instructions
Author Summary
The clinical outcome of DENV infection in humans can be
DF or the more severe DHF and DSS. The individual’s
previous DENV exposure history, infecting serotypes, and
host genetics are thought to be contributing factors to
dengue disease severity. Our study contributed to the
current dengue research field in the following ways: 1) Our
study reveals the dynamics of host gene expression over
each day post onset of symptoms. The gene transcription
patterns enabled classification of dengue disease into 2
subtle phases: early acute and late acute. 2) The study
identified gene markers differentiating severe dengue
cases from non-severe cases with .90% accuracy. Taken
together, our study offers insight into host responses in
DENV-infected subjects and these results may be valuable
for the future development of diagnostic tools for disease
severity.
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(Qiagen Inc., Valencia, CA, USA). Briefly, the TaqManH One-Step
RT-PCR Master Mix Reagents (PN:4309169, Applied Biosystems)
were prepared in the following manner: final concentration of primers,
1 mM; probes, 0.22 mM in a final reaction volume of 25 ml [19].
Thermocycling was set to 50uC for 30 min and 95uC for 10 min,
followed by 45 cycles of 95uC for 15 sec and 60uC for 1 min. The PCR
reactions were performed in a 7500 Real-Time PCR System (Applied
Biosystems). DENV serotype-specific RT TaqMan PCR was
performed on the acute samples using a protocol previously described
by Laue et al: a standard curve for eachDENV serotype was developed
using four DENV representative strains (one for each serotype). The
starting concentration followed a ten-fold dilution of each serotype:
serotype 1 (16007)= 2.36106 PFU/ml; serotype 2 (16681) =2.56107
PFU/ml; serotype 3 (IQD1728)=4.86105 PFU/ml and serotype 4
(1036)=4.66105 PFU/ml.
Gene expression profile analysis using Affymetrix gene
chips
Extraction of cellular RNA, assessment of the integrity and
quantity of the extracted RNA, and subsequent processing of the
RNA for gene array were performed using the Agilent 2100
Bioanalyzer system (Agilent Technologies, Santa Clara, CA) as
previously described [20,21]. Two chip types were used in the
study: Affymetrix HG-U133 plus 2 and HG-Focus. The HG-
U133 plus 2 contained 54,675 probe sets, where each set
consisted of 11 25-mer probes. The HG-Focus gene chip is
consisted of 8,793 probe sets to assess 8,500 transcripts encoding
8,400 full length and fully annotated genes [20,21]. The 8793
probe sets of the HG-Focus are a subset of the probe sets from
HG-U133plus2.
GeneChip quality control and data normalization
Gene chips with a scaling factor .50 on the dChip software
(2005 version) were eliminated from further analysis [21,22]. Gene
chips were also examined using the QA/QC functions built into
the Partek software according to the Company’s User Manual.
Affymetrix CEL files were imported into Partek Genomics Suite
Version 6.6 (Partek). The gene chips that failed according to the
QC metrics and appeared as outliers using principal component
analysis (PCA) were eliminated for further analysis. The CEL files
were normalized at the probe level using the Robust Multi-chip
Average (RMA) method built into the Partek Genomic Suite
software. RMA was used to normalize the microarray data, which
leveraged the gene expression assessments made on Affymetrix
gene chips. For each probe set, the technique generated an
estimated value for the probe and chip effects, which resulted in an
overall pattern of probe set values observed in the data set. RMA
consisted of 3 calculation applications that address background
correction, normalization of the quantiles, and median polish
summarization. The gene expression data were expressed as log2
values. The data sets from the two gene chip platforms were
normalized and analyzed independently.
Differentially expressed genes
Differentially expressed genes were analyzed using analysis of
variance (ANOVA) using the Partek software. Multi-way
ANOVA was chosen based on the number of factors contributing
to data variation. The following factors were taken into
consideration as variation factors: subject #, scan date (date that
the chip image was taken), infecting serotype, illness day (days of
illness when the sample was taken), and disease severity (samples
associated with the DF or DHF category). Genes that were
considered significant only by chance were defined by the false
discovery rate (FDR$5%) and were excluded from further
analysis. In this study, the genes with a fold change of .2 or
,22 and a p-value plus a FDR ,5% were considered
significant. A heat map and PCA were used to visualize the
most informative trends by showing the predominant gradients in
the data set.
Gene ontology and functional pathway
Analysis of the gene biological functions and pathways were
performed using the pathway analysis modules in the Partek
Genomic Suite 6. Two analysis modules were used: gene ontology
(GO) [23] and KEGG pathway [24]. The gene ontology/
biological process level-5 (GOTERM_BP_5) [25] was used for
the GO analysis. The Database for Annotation, Visualization and
Integrated Discovery (DAVID), an online program for microarray
data mining developed by NIAID was used as a second tool for
gene function and pathway analysis.
Classification
Class prediction was performed using the Partek Model
Selection tool in the Partek software. Using this software, nested
cross-validations were used to select an optimal classifier and to
estimate the accuracy of the optimal classifier when multiple
classifiers were considered for a single problem. For the 2-level
cross-validation, an ‘‘inner’’ cross-validation was performed to
select predictor variables and optimal model parameters, and an
‘‘outer’’ cross-validation was used to produce overall accuracy
estimates for the classifier. Following the 2-level cross-validation
method, the 1-Level Cross-Validation was used to evaluate
multiple models and to select the best model to deploy. In this
study, the 2-level nested cross validation process used ANOVA or
Shrinking Centroid to filter the data. Multiple groups of variables
with specified sizes were evaluated. The best classification model
was determined by running the following classifiers: K-nearest
neighbors with 1–25 neighbors, Nearest Centroid, Discriminant
Analysis, and Support Vector Machine.
Results
Clinical information of the study population
From 2006 to 2010, approximately 300 febrile individuals in
Maracay, Venezuela, who presented themselves at participat-
ing clinics and hospitals or were identified by community-
based monitoring, with signs and symptoms consistent with
dengue disease, met the study enrollment criteria. These
individuals were subsequently enrolled into the study. Approx-
imately 130 subjects were confirmed by PCR of DENV
infection and were categorized as DF and DHF patients
according to the WHO 1997 dengue disease classification
guidelines. DHF patients were recognized based on fever,
bleeding, thrombocytopenia (platelet counts #100,000) and
signs of plasma leakage. Subjects who had $3 serially collected
samples, 1 at each of the febrile, defervescent and convalescent
stages were selected for the study, thus we had 51 DF and 13
DHF subjects providing a sum of more than 200 samples for
the study. The demographics of the study participants and
their clinical, immunological and hematological characteristics
are summarized in Table 1. The timing of the collection,
serotype, and severity, related to the samples are presented in
Table 2. To assess the statistical difference between DF and
DHF, hypothesis testing of 2 independent samples with
unknown variances was performed for mean values, and
hypothesis testing for 2 sample proportions was performed for
percentages. As shown in Table 1, most of the DHF cases met
Genetic Markers of Dengue Disease Severity
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all 4 classification criteria. The percentages of lymphocytes and
neutrophils in the peripheral blood of DF and DHF patients
were plotted in Figure S1.
Day-to-day host gene expression depicted two sub-
phases during the process of the disease
A total of 166 specimens from 47 DF and 3 DHF subjects were
used to study the dynamics of host responses using the HG-focus
gene chip platform (Table 2).
To analyze the dynamics of the host response in DENV-
infected individuals, samples obtained at different illness days
were grouped together into stages (G). Group sizes (# of
specimens) were shown by G and also by serotype or severity
(Table 2). As illustrated in Figure 1a, G0 was the day of fever
onset, G1–G5 corresponded to 1–5 days from fever onset, G6
was day 6–10, and G7 was the convalescent time point day
$20. As shown in Figure 1a, each G had $19 samples except
G0 and G1. Using levels of gene expression at G7 as the
baseline, significantly up- or downregulated genes were detected
at each G using 5-way ANOVA (Subject #, scan date, severity,
stage, and serotype as 5 factors). The number of significant
genes in each G from G0–G6 was 360 (G0), 320 (G1), 92 (G2),
136 (G3), 122 (G4), 198 (G5), and 152 (G6), respectively.
Combined, these genes consisted of a total of 615 genes (7.0% of
8793 probe sets on the FG-focus platform) representing the total
up- or down regulated genes activated throughout the entire
illness period. Visualizing the expression patterns of the 615 in
all of the samples at all time points using PCA, we observed that
Table 1. Clinical, immunological and virological information of study cohorts.
Gender and Age DF (n =51) DHF (n =13) p value
Sex: Female, No (%) 27 (52.9) 10 (76.9) 0.19
Age: Mean years 6SD (range) 15.367.1 (5–32) 19613.4 (5–49) 0.35
Infecting Serotype1
DENV-1, No (%) 26 (50.9) 2 (15.4) 0.33
DENV-2, No (%) 8 (15.7) 8 (61.5) 0.06
DENV-3, No (%) 9 (17.7) 2 (15.4) 0.94
DENV-4, No (%) 7 (13.7) 1 (7.7) 0.87
Pre-existing DENV infection2
None, No (%) 23 (45.1) 2 (15.4) 0.42
One serotype, No (%) 13 (25.5) 1 (7.7) 0.69
Two serotype, No (%) 10 (19.6) 6 (46.1) 0.26
Three serotype, No (%) 4 (7.8) 4 (30.8) 0.41
Symptoms
Hospitalization, No (%) 8 (15.7) 10 (76.9) ,0.01
Temp Max uC 6 ST DEV 38.960.7 39.160.7 0.37
Fever Days 6 ST DEV 4.361.1 5.261.0 ,0.01
Headache, No (%) 50 (98.0) 13 (100) 0.61
Shivering, No (%) 43 (84.3) 10 (76.9) 0.58
Rash, No (%) 37 (72.6) 8 (61.5) 0.53
Cough, No (%) 12 (23.5) 4 (30.8) 0.77
Diarrhea, No (%) 10 (19.6) 6 (46.2) 0.26
Nausea, No (%) 19 (37.3) 7 (53.8) 0.45
Hematology
Thrombocytopenia
(platelet #100,000/mm3), No (%) 8 (15.7) 12 (92.3) ,0.01
Plasma leakage3, No (%) 6 (11.8) 7 (61.5) ,0.01
Bleeding4, No (%) 23 (45.1) 13 (100) ,0.01
Viral Load (Mean ± ST DEV)
Day 0 (No) - - -
Day 1 (No) 1.4E+0462.8E+04 (7) - -
Day 2 (No) 7.4E+0362.8E+04 (27) 3.2E+0365.4E+03 (3) .0.05
Day 3 (No) 4.2E+0261.4E+03 (21) 1.6E+0664.6E+06 (9) .0.05
Day 4 (No) 0.7E+0162.4E+01 (14) 1.1E+0462.7E+04 (6) .0.05
1Serotype for 1 DF subject was missing due to a suspected non-DENV infection.
2PRNT for 1 DF subject was not done.
3Elevated hematocrit comparing the highest to the lowest values recorded, or other signs of plasma leakage (pleural effusion, ascites, or other edema).
4Tourniquet test or signs of epistaxis, ecchymosis, gum bleeding, hematemesis, hemoptysis, genital bleeding, or other bleeding.
doi:10.1371/journal.pntd.0002298.t001
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gene expression patterns gradually shifted by stages from G0 to
G6 (Figure 1b). Within this gradual shift, G0, G1, G2, and G3
formed a cluster that was clearly distinguishable from that of G5
and G6. The samples from G4 bridged between the two clusters.
To determine whether the change of gene expression, especially
the two distinguishable clusters, was modulated by the presence or
absence of fever, we performed PCA on only the defervescent
samples. As shown in Figure 1c, the majority of the G4–G6
defervescent samples clustered together, while 4/5 G2–3 and some
G4 defervescent samples separated (Figure 1c), suggesting that
defervescent samples from a shorter febrile duration (2–3 days)
maintained gene expression patterns that were more similar to
those of early febrile samples. Similarly, when PCA analysis was
performed only on the febrile samples (Figure 1d), it was clear that
all of the 5 G5–6 samples, together with a few of the G4 febrile
samples separated from the rest of G0–G4 febrile samples, and
maintained a pattern more similar to that of late defervescent
samples.
Based on the 2 distinguishable clusters shown in Figure 1b, we
regrouped the samples into early acute (G0–G3), late acute (G4–
G6) and convalescent phases (G7). A second 4-way ANOVA was
performed by comparing the gene expression in the early acute vs.
convalescent and late acute vs. convalescent phases. We identified
223 and 140 significant genes that were differentially expressed in
the early acute and late acute phase, respectively (Figure 1e, Table
S1 and S4). Only 25 genes (,8%), as shown by a Venn Diagram
(Figure 1e), were shared between the early and late phase,
indicating persistent expression of these genes; whereas the
majority (,92%) of the genes (198+115= 313) were uniquely
expressed in either the early or late phase (gene list shown in Table
S7). These phase-unique markers showed a better separation of
the 3 phases (Figure 1f): early acute, late acute and convalescent.
To validate our observations, we performed a similar analysis
for the samples assayed using another chip type: HG-U133plus2
(sample information shown in Table 2), and similar results were
obtained (Figure S2a–c). We further separated the DF and DHF
samples and analyzed them separately. The gradual change in
gene expression over time and the clustering of G1–G3 and G4–
G6 were both observed in the DF and DHF groups (Figure S3),
suggesting that the time of sampling contributed most significantly
to gene expression variation.
Functionally categorizing differentially expressed genes
in early and late acute phases
To understand the functions of the differentially expressed
genes identified by ANOVA, gene ontology (GO) and Kegg
pathway analysis was used to annotate the functional profiles.
The entire list of GO categories in the early and late acute phases
with a pathway p-value ,0.01 and with more than 3 involved
genes are shown in Tables S2, S3, S5, and S6. Listed in Table 3
are the most significant pathways with the highest enrichment
scores as detected using the HG-focus gene chip platform. As
shown in Table 3, genes upregulated in G0–G3 were related to
the innate immune pathways, type-I interferon-mediated signal-
ing, cytokine-mediated signaling, response to virus, chemotaxis,
and inflammatory responses. Gene down-regulated in G0–G3
were related to gene transcription and translation, cellular protein
metabolic processes, structural constituent of ribosome, viral
transcription, and viral infectious cycle. Genes upregulated in
G4–G6 were related to mitotic cell cycle, cell division, mitosis,
DNA replication, chromosome, spindle organization, phosphati-
dylinositol-mediated signaling. Strikingly, there was minor
overlap between early acute and late acute phases in terms of
gene functionality.
Table 2. Sample information on two gene chip platforms.*
Array by severity by serotype
Platform G All DF DHF DENV1 DENV2 DENV3 DENV4
G0 2 2 0 0 1 1 0
HG-focus G1 4 4 0 2 0 1 1
G2 21 20 1 14 2 3 2
G3 19 19 0 9 4 4 1
G4 24 21 3 12 4 5 4
G5 23 22 1 14 1 3 3
G6 26 25 1 18 0 7 1
G7 50 47 3 25 6 9 6
Total 166 157 9 95 18 33 18
G0 0 0 0 0 0 0 0
HG-U133 G1 2 2 0 0 2 0 0
plus 2** G2 8 5 3 1 5 1 1
G3 14 7 7 2 8 1 2
G4 18 8 10 3 10 3 2
G5 9 4 5 4 5 0 0
G6 22 11 11 7 7 5 3
G7 24 12 12 7 11 3 3
Total 97 49 48 24 48 13 11
*Tables shows number of samples per category.
**Among 97 samples tested on HG-U133plus2, 50 were also tested on HF-focus.
doi:10.1371/journal.pntd.0002298.t002
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Figure 1. Daily gene expression patterns define 2 subtle phases during the disease process. a) Illness days with corresponding stages (G)
and phases for samples on the HG-focus platform. The number of febrile and defervescent samples in each G was shown. b) A global overview of the
gene expression pattern in G0 to G7. Using convalescent samples (G7) as a baseline, significant genes in each stage (from G0 to G6) were detected
using multi-way ANOVA. PCA was performed using all of the significant genes found in G0 to G7 on the HG-focus platform. All of the samples
(represented by dots) were included in the PCA. c) PCA was performed on the defervescent samples only. d) PCA was performed on the febrile
samples only and are indicated according to the number of fever days. e) Samples were reassigned to the early acute, late acute and convalescent
phases. Differentially expressed genes in the early acute vs. convalescent or late acute vs. convalescent phase were detected using multi-way ANOVA.
Shared genes between the early and late acute phases were represented by a Venn diagram. f) PCA was performed using 313 phase-specific genes.
doi:10.1371/journal.pntd.0002298.g001
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The GO analysis using genes expressed on HG-U133plus2
showed same GO pathways as those on HG-focus, reemphasizing
the reproducibility of the data (Table S8).
Furthermore, two of the top Kegg pathways representing the
early acute and late acute phases were the Systemic Lupus
Erythematosus (SLE) (Figure S4) and Cell Cycle (not shown)
pathways, respectively. SLE is an autoimmune disease associated
with type III hypersensitivity. It is triggered by the precipitation of
antibody immune complexes to cells and tissues, causing
complement activation, immune cell activation, and inflammation,
and results in tissue and organ damage. Genes encoding
complement components C2, C1q and C1r and genes associated
with antigen processing and presentation, cytokine-cytokine
signaling, T cell receptor signaling, cell adhesion, complement
coagulation, and all those marked with a red star, were present in
G0–G3.
Genomic signatures predictive of 3 dengue disease
phases with 91% accuracy
For the classification of dengue disease phases, 2-level cross-
validation using all of the data on the HG focus chips returned a
Normalized Accuracy Estimate = 88%. The 1-level cross-validation
returned a top model which used 65 variables and yielded a
Normalized Correction Rate of 91% (Figure 2a). These results
showed that a set of 65 variables classified early acute, late acute and
convalescent phases with an accuracy of 91% (Figure 2b). Among
these 65 genes, 23 and 27 variables were unique gene signatures for
the early acute and late acute phase, respectively, whereas 15
variables were expressed in both the early and late acute phases.
We also performed classification analysis with samples on the
HG-U133plus2 platform and found that 55 out of these 65 phase
classifiers were also (Table S9) found on this platform.
Sequential waves of marker expression
The dynamics of the expression of these 65 markers from G0–
G7 were analyzed and shown in Figure 3. Markers belonging to
the early acute phase peaked at G0–G1 and gradually declined to
baseline around G4–G5; whereas markers unique for the late
acute phase emerged at G4 and peaked at G5–G6. These results
showed two sequential waves of genes representing two host
response periods: an innate response period followed by a cell
mitotic cycle period. The cross-point of the two waves was at G4.
A list of the top 7 genes with 96% accuracy in predicting
DF vs. DHF
We further analyzed the data on the HG-U133plus2 chips for
gene expression related to DF vs. DHF. Classification analysis was
first performed using all of the genes on the HG-U133plus2 chip
for samples in G0–G3. A total of 140 genes (Table S10) classified
DF vs. DHF with a correction rate of 86% using the classification
methods of K-nearest Neighbor with Euclidean distance and 3
neighbors. The fold changes of the 140 genes between DF and
DHF were .2 or ,2 with p (FDR) ,0.05 by ANOVA analysis
(Table S10). Among these 140 genes, 79 genes (59%) showed
higher levels of expression in the DF samples compared to the
DHF samples; whereas 61 genes (41%) showed higher levels in the
DHF samples compared to the DF samples (Table S10). Antigen
processing and presentation of the peptide or polysaccharide
Table 3. Common and differential GO pathways in early acute and late acute phases.
Phase Up-regulated GO pathways Down-regulated GO pathways
Early Acute type I interferon-mediated signaling pathway translational elongation
cytokine-mediated signaling pathway translation
immune response structural constituent of ribosome
interferon-gamma-mediated signaling pathway viral transcription
innate immune response translational termination
double-stranded RNA binding cellular protein metabolic process
response to virus viral infectious cycle
chemotaxis gene expression
inflammatory response endocrine pancreas development
defense response to virus ribosome
Late Acute mitotic cell cycle positive regulation of nitric oxide biosynthetic process
cell division positive regulation of fever generation
mitosis peroxidase activity
spindle organization haptoglobin-hemoglobin complex
cell cycle sequestering of triglyceride
DNA replication positive regulation of calcidiol 1-monooxygenase activity
M phase of mitotic cell cycle humoral immune response
phosphatidylinositol-mediated signaling oxygen transport
chromosome regulation of I-kappaB kinase/NF-kappaB cascade
cell cycle checkpoint
Both phases cytokine-mediated signaling pathway
type I interferon-mediated signaling pathway
response to virus
doi:10.1371/journal.pntd.0002298.t003
Genetic Markers of Dengue Disease Severity
PLOS Neglected Tropical Diseases | www.plosntds.org 7 July 2013 | Volume 7 | Issue 7 | e2298
antigen via MHC class II, MHC class II protein complex,
interferon-gamma-mediated signaling pathway, T cell receptor
signaling pathway, MHC class II receptor activity, and T cell co-
stimulation were among the top functional bio-pathways with a
higher level expression in DF specimens compared to DHF
specimens (Table 4).
Figure 2. 2-level and 1-level cross-validation identified a top classification model and 65 gene signatures for the prediction of 3
phases. a) Information of the model selection showing 65 variables and a top classification model with 2-level and 1-level normalized correction
rates. b) Heatmap of the 65 signatures.
doi:10.1371/journal.pntd.0002298.g002
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Since our ultimate goal was to discover markers for the early
diagnosis of DHF, we sought markers expressed differently
between DF and DHF throughout G1 to G3, but not the ones
different in only one or two stages. The median level of gene
expression for each of the 140 genes in G1, G2 and G3 for the
DF and DHF group, respectively, was analyzed. There were 56
(out of 140) genes met this criterion with a fold change of .2
or ,22 throughout G1 to G3 compared to G7. Ranking of the
56 genes revealed 7 genes (Table 5) that differentiated DF from
DHF with a 96% accuracy. PCA using these 7 genes clearly
segregated the DF from the DHF samples (Figure 4a). The
dynamic expression of these 7 genes was shown in Figure 4b.
Discussion
The samples collected in this study spanned from as early as the
first day of fever onset to early defervescent to the convalescent
period. They provided an exceptional opportunity to investigate
the whole spectrum of host responses during the disease process.
The samples from earliest time points were particularly valuable in
understanding the differences in pathology between DF and DHF
at early stages of disease.
Clinical, immunological and hematological information
of DF and DHF cohorts
The classification of DF and DHF cases played a key role in
this study. We followed the 1997 WHO guidelines: persistent
high fever, hemorrhagic manifestations (spontaneous bleeding),
thrombocytopenia (platelet counts #100000/mm3), and signs
of plasma leakage ($20% increase in hemoconcentration,
pleural effusion or ascites). Most of our DHF cases met all 4
criteria.
Other differences characterizing DHF from DF included a
prolonged fever duration (5.2 vs. 4.3 days), higher hospitalization
rate, higher secondary infection rate, and a trend of higher viremia
titers, which were all consistent with our current knowledge
[9,26,27].
In all patients, there was a decrease in lymphocytes but an
increase in neutrophils within the first 1–3 days of illness
compared to the convalescent baseline (G7). Changes in the
lymphocytes and neutrophils were significantly more pro-
nounced in the DHF compared to the DF cases. Potts et al
attempted to use hematological measures for diagnosis of
severe dengue illness [28]. They found that higher counts of
neutrophils and lower counts of white blood cells within 3 days
from the onset of illness predisposed people at a higher risk of
DHF. Mechanistically, early stage T cell apoptosis [29,30]
demonstrated by Green et al. may account for the lower
lymphocyte counts. T cell apoptosis may also account for the
lack of functional CD8+ T cell cytokine production [31], and
lack of T cell proliferation at the febrile period of dengue
illness [32]. Taken together, these data support the role of
cellular immunity in the defense against dengue disease
severity, and provided some biological insights on our gene
array results, which are later discussed. Neutrophils are one of
the first cells to migrate to infection sites; they play an
Figure 3. Two waves of gene expression over the disease stages. Median marker expression intensity (log 2 value) of the genes detected in
the early and late acute phases from G0 to G7 was shown.
doi:10.1371/journal.pntd.0002298.g003
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important role in the control of various bacterial and viral
infections though phagocytosis and cytokine/chemokine pro-
duction [33]. Neutrophils release an array of cytokines and
chemokines to impact the functions of other cells of the innate
as well as the acquired immune system [34,35]. The changes of
neutrophil counts in early stages may provide mechanistic
insights for our gene array study, as the chemokine and
inflammatory cytokine responses are the top functional gene
pathways in early acute phase.
Two waves of gene expression representing two
distinctive phases of disease process
We observed a gradual evolution in the gene expression patterns
over time from G0 to G6 with a more significant change at G4,
resulting in the separation of the early acute (G0–G3) and late
acute phases (G4–G6). This was independent of disease severity
and was incompletely associated with fever status. The early acute
and late acute phases were represented by two waves of
functionally distinct gene clusters: the innate immunity followed
by cell cycle. Strikingly, only 10% genes were shared between the
two phases, and .90% of the genes were unique for either the
early or late phase.
A number of published dengue gene array studies [11,12]
have highlighted the importance of sampling time and
addressed the difference with respect to timing. However,
there is not a uniformed and clear method in the timing of the
samples. Some studies used #72 hours to define the early
phase, while others treated samples from various days as one
group. Furthermore, due to the limitation of their sample bank
(most of the studies had samples from day 3–6), the studies did
not show an evolving picture of gene expression on a day-to-
day basis, and were mostly unable to capture both waves of
gene expression [11,13,36,37]. Their findings highlighted a
specified period of dengue disease. To the best of our
knowledge, we are the first study to present the host response
to dengue infection as an entirety.
Nevertheless, when we examined our results and those of
others by breaking down to separate phases, we found that our
results and those of others were mutually supportive. Hoang et
al. had used samples collected within 72 hours of the illness
from Vietnam, and had identified major functional pathways,
response to virus, immune response, innate immune response
and inflammatory responses, which were nearly identical to
those found in our study. Fink et al. conducted a study on
dengue febrile subjects in Singapore [11]. Approximately 50%
of their 32 reported innate immunity genes, including TNF,
IP-10 (CXCL10), I-TAC (CXCL11), Stat 1, OAS1, OAS2,
OAS3, OASL, IFIH1, IFI44, UBE2L6, UPS18, HERC5,
ISG15, PSMB9, MxA (Mx1) were also identified during the
same period of disease G0–G3 in our study. More interesting-
ly, IP-10 (CXCL10) gene was one of the most upregulated
genes demonstrated in both ours and Fink’s study. In addition,
Simmons et al. used samples from day 3–6 with a mean length
of illness of 4.6 days from hospitalized patients in Ho Chi Minh
City, Vietnam [12]; Loke et al. studied gene expression using
samples within 3–6 days of illness from children in Nicaragua.
The presence of genes related to cell cycle, protein metabolism
and nucleic acid metabolism in these two studies confirmed
our observation of the late acute phase. Our results suggested
that future studies should consider carefully the time of sample
collection since host responses at early acute and late acute
phases showed little in common.
Table 4. GO pathways of gene signatures which differentiated DHF from DF.
Pathways Up/down Enrichment Enrichment
Df vs DHF Score P value
antigen processing and presentation of peptide or polysaccharide
antigen via MHC class II
Up 24.2904 0.000000
MHC class II protein complex Up 23.8583 0.000000
interferon-gamma-mediated signaling pathway Up 21.9241 0.000000
T cell receptor signaling pathway Up 17.1104 0.000000
MHC class II receptor activity Up 16.7737 0.000000
cytokine-mediated signaling pathway Up 15.0755 0.000000
lysosomal membrane Up 14.6264 0.000000
T cell costimulation Up 14.5901 0.000000
Golgi apparatus Up 11.4283 0.000011
type 2 fibroblast growth factor receptor binding Down 10.1483 0.000039
regulation of branching involved in salivary gland morphogenesis by
mesenchymal-epithelial signaling
Down 10.1483 0.000039
surfactant homeostasis Down 9.38874 0.000084
branching involved in salivary gland morphogenesis Down 9.00746 0.000122
killing of cells of other organism Down 9.00746 0.000122
defense response to fungus Down 8.84125 0.000145
phosphatidylcholine biosynthetic process Down 8.68795 0.000169
defense response to bacterium Down 8.68049 0.000170
hair follicle morphogenesis Down 7.50439 0.000551
response to virus Down 6.96488 0.000944
doi:10.1371/journal.pntd.0002298.t004
Genetic Markers of Dengue Disease Severity
PLOS Neglected Tropical Diseases | www.plosntds.org 10 July 2013 | Volume 7 | Issue 7 | e2298
Figure 4. Classification of DF and DHF. a) The expression pattern of the top 7 genes (selected from 140 genes) is indicated using PCA. b) The
dynamic expression (shown by median Log2 gene expression intensity) of 7 DF-DHF signatures from G1 to G7.
doi:10.1371/journal.pntd.0002298.g004
Table 5. List of top 7 genes differentiating DF from DHF with 96% accuracy.
Probeset Gene Gene Title p-value Fold-Change Up/down
ID Symbol (DF vs. DHF) (DF vs. DHF)
1556842_at LOC286087 hypothetical protein LOC286087 0.0002 4.0401 DF up vs DHF
203908_at SLC4A4 solute carrier family 4, sodium bicarbonate cotransporter, member 4 0.0001 2.0548 DF up vs DHF
205048_s_at PSPH phosphoserine phosphatase 0.0000 8.1003 DF up vs DHF
205826_at MYOM2 myomesin (M-protein) 2, 165 kDa 0.0004 4.9076 DF up vs DHF
219714_s_at CACNA2D3 calcium channel, voltage-dependent, alpha 2/delta subunit 3 0.0008 2.4949 DF up vs DHF
220307_at CD244 CD244 molecule, natural killer cell receptor 2B4 0.0001 2.1211 DF up vs DHF
225219_at SMAD5 SMAD family member 5 0.0003 2.1587 DF up vs DHF
doi:10.1371/journal.pntd.0002298.t005
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The two waves of genes possibly implicate two stages of
host response: anti-viral response and post-infection
recovery
The switch in major biological processes from innate
immunity to cell mitotic cycle at G4 occurred at G4. It
appeared that this switch coincided with a decrease in viremia.
As shown in Table 1, viremia decreased to low levels in most
dengue cases at around G3–G4. Genes related to the viral
replication cycle, RNA synthesis and RNA transcription were
downregulated in G0–G3, which coincided with the upregula-
tion of innate immune responses during this phase. It is known
that anti-viral inflammatory cytokines and soluble factors, IL-1,
-6, -8 and -10 or TNFa and c, MIP-1a and c or VEGF [38–42],
and the nitrogen and oxygen species [43], were present in
patient sera. Our study suggested a vital role of type I IFN
responses, anti-viral responses, as well as chemokines, chemo-
taxis and complement activation in suppressing viral replication.
Apoptosis of DENV-infected cells has been demonstrated in
vitro or in vivo in almost every single type of cells infected by
DENV. Studies using PBMCs from dengue patients show that
T cells undergo activation and apoptosis during the acute
illness phase when viremia was present. Impaired CD8+ T cell
activity [31], decreased circulation of CD4+ and CD8+ T cell
counts, impaired T cell proliferation [30,32], and increased T
cell apoptosis, were all demonstrated during the acute phase.
Restoration of T cell activities, T cell counts, and cytokine
production was detected from day 5 onward [29–32], which
coincided with the absence of viremia in vivo. In our study, the
patients also showed a decrease in lymphocytes during G0–G3,
which subsequently returned to above baseline levels. Al-
though they were not the top categories, apoptotic pathways,
including the activation of pro-apoptotic gene products,
response to unfolded proteins, activation of caspase activity,
release of cytochrome C from the mitochondria, and induction
of apoptosis by extracellular signals were upregulated during
the early acute phase, supporting previous in vitro and in vivo
observations on cell apoptosis during early days of infection.
The subsequent upregulation of genes related to DNA
synthesis and the mitotic cell cycle in G4–G6 suggests a
period of immune cell recovery, which may begin when
viremia has significantly decreased.
Biological pathways identified using proteomics and
genomic pathways
Our previous proteomics study revealed several serum
biomarkers that predicted DHF. One of these markers was
the complement component C4a [44]. Although direct
expression of C4a gene was not detected, its upstream
complement components, C1q and C2, and other factors such
as HF1, BF1, CD59 and SERPING1 were detected in the early
acute phase. The complement system can be activated by a
classical immune complex (IC) -dependent pathway, an
alternative pathway and a lectin pathway. Activation of the
complement system restricts viral or bacterial infection, but it
also promotes strong inflammatory responses. Complement
C1q- or C3 have been shown to eliminate ADE [45]. In
dengue patients, the peak presence of C3a and C5a coincided
with the onset of shock and leakage. In addition, the levels of
C3a correlated well with disease severity [46]. By capturing
genes in the complement pathways, our study highlighted the
involvement of the complement system in the early acute
phase. Since most DHF cases are secondary infectious cases,
the involvement of the complement system in dengue disease
severity requires further investigation.
Markers of disease severity
We found a set of 140 genes that distinguished DF from DHF
with 86% accuracy. Genes expressed more abundantly in DF were
associated with antigen processing and presentation, such as the
MHC class II protein complex, interferon-gamma-mediated
signaling, T cell receptor signaling, and T cell co-stimulation
pathways.
Seeking gene markers for severe dengue disease has been an
exclusive goal in nearly every gene array study conducted. For
those studies which used samples collected from day 3–6, their
results differed from our findings [13]. Popper et al. recently
performed a second gene array study in Nicaragua, where they
investigated gene expression in a day-to-day manner [37]. They
showed that on fever day 3, lower levels of IFN-stimulated gene
transcripts were associated with the development of DSS. The
results from this study showed some consistency with our findings.
Nascimento et al. conducted a gene array study on a well-
characterized dengue cohort from Recife, Brazil [47]. Their results
also showed that at early stages of DENV infection, the genes
involved in the effector functions of innate immunity were weaker
in DHF patients. Furthermore, Devignot et al. showed that genes
related to T and NK cell responses were decreased and genes
related to anti-inflammatory and repair/remodeling were in-
creased in DSS patients in a study in Cambodia [48]. Overall, the
results generated from our study and from those previously
reported illustrate an association of IFN-c and T cell immunity
with lower risk of DHF.
In our study, the majority (61.5%) of DHF cases were caused by
DENV-2. In contrast, 50% DF cases was due to infection with
DENV-1. We were unable to identify differences in the gene
expression pattern between any of the two serotypes (data not
shown). Thus, different serotypes may not be the main cause
underlying the differential gene expression patterns associated with
DF or DHF.
The association of cellular immunity with DF, but not DHF,
strengthened the protective role of cellular immunity against the
severity of dengue disease. Since most of the DHF cases were
secondary infections, theoretically, cellular immunity should be
more rigorous due to the presence of T cell memory. It is known
that DENV primarily infects monocytes, macrophages and
dendritic cells. These cells are antigen-presenting cells responsible
for antigen processing and presentation. Apoptosis caused by
DENV infection of these cells may account for the decrease in
lymphocytes in the peripheral blood during the early acute phase
of the disease and may explain the weakened gene expression of
cellular immunity in DHF patients.
For future diagnostic purposes, we selected 7 genes that were
able to differentiate between severe and non-severe dengue disease
with a high accuracy (96%). These genes were selected on the basis
of their consistent expression throughout the early acute days (G1
to G3). The CD244 gene encodes a cell surface receptor expressed
on natural killer (NK) cells (and some T cells) that mediate non-
major histocompatibility complex (MHC) restricted killing. The
interaction between NK-cells and target cells via this receptor was
thought to modulate NK-cell cytolytic activity. The SMAD5 gene
encoded protein is involved in TGF-b signaling, which results in
an inhibition of the proliferation of hematopoietic progenitor cells.
In addition, CD244 and SMAD5 genes were both downregulated
in DHF subjects. The CACNA2D3 gene encodes a member of the
alpha-2/delta subunit family, a protein involved in the voltage-
dependent calcium channel complex.
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Conclusion
To the best of our knowledge, this study was the first study to
present a systemic analysis of the full dynamics of the host response
in dengue clinical subjects. This study was completed using two
chip platforms and obtained highly consistent results between the
two platforms. The gene microarray analysis was supported by
clinical observations, comprehensive hematological test results, as
well as viremia and immunology data. This study also provided
solid data to highlight the importance of the timing in the
collection of the clinical samples. This study also strengthened the
role of IFN-c and T cell immunity in the defense against DHF.
Our results will advance the understanding of the DENV-
mediated disease progression, which will provide enormous
support for future clinical research, diagnostics and vaccine
development.
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each stage from G0 to G6 were defined as the fold change between
Gn to G7:.2 or,22 and p-value with false discovery rate (FDR)
,0.05. S1a). PCA performed with significant genes in all of the
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the early acute and late acute samples on the HG-U133 plus2
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for groups of DF and DHF subjects. Using convalescent samples
(G7) as a baseline, significant genes in each time point were
detected using multi-way ANOVA for DF or DHF group. PCA
was performed using all of the significant genes found in G0 to G7
within each group on the HG-U133 plus 2 platform. a) PCA
profiling for the DF group. b) PCA profiling for the DHF group.
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from the HG-U133plus2 platform. The red stars mark the genes
or pathways present in the data.
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